---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-006832"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T00:45:47.036399+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CervoMed announces positive Phase 2b extension results for neflamapimod in DLB

## Summary
- New capsule batch yielded higher plasma levels; CDR-SB improved vs old capsules (p<0.001) and vs placebo (p=0.003).
- CGIC score improved with new capsules vs old (4.02 vs 4.46, p=0.035); within-subject placebo comparison also significant (p=0.035).
- Fall incidence lower with new capsules (7.4%) vs old (14.5%) and vs placebo (18.8%, p=0.04); in ptau181 <2.2 subgroup: 4.0% vs 19.7% (p=0.007).
- 149 patients entered extension; 94 received new capsules; completion rates 87.3% (old) and 91.5% (new); no new safety signals.
- Company plans to complete full 32-week extension and discuss Phase 3 plans with regulators later this year.

## SEC filing metadata
- accession: 0001437749-25-006832
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774925006832/0001437749-25-006832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774925006832/crvo20250310_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-006832
- JSON: https://secwatch.observer/filing/0001437749-25-006832.json
- Plain text: https://secwatch.observer/filing/0001437749-25-006832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.